Skip to content
Clinical Trials – home
Therapeutic area

Gastrointestinal disorders – page 7

  • 1 122 clinical trials
  • 491 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Clinical trials in Gastrointestinal disorders

1 122 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 122 clinical trials

Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Guselkumab
  • Sponsor:Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Methotrexate
  • Sponsor:Amsterdam UMC Stichting
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epinephrine
  • Sponsor:Centre Hospitalier Universitaire De Nimes
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:UZ Leuven
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan Hydrochloride Trihydrate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Kyv-101
  • Sponsor:Kyverna Therapeutics Inc.
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Amsterdam UMC Stichting
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Smartwise Sweden AB

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.